SEC For	m 4																			
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549													MISSION OMB APPR				
Check Section obligat Instruc	ST	FILED														erage burder	0.5			
1. Name and Address of Reporting Person* Mitchell Stephen Ray					2.	2. Issuer Name and Ticker or Trading Symbol <u>Vanda Pharmaceuticals Inc.</u> [VNDA]									5. Relationship of Re (Check all applicable X Director			on(s) to Issi 10% Ow		
(Last) (First) (Middle) C/O VANDA PHARMACEUTICALS INC.						3. Date of Earliest Transaction (Month/Day/Year) 09/09/2021									 Officer (give title Other (specify below) below) 					
2200 PENNSYLVANIA AVENUE, SUITE 300E					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WASHINGTON DC 20037					_	Form									iled by One Reporting Person iled by More than One Reporting 1					
(City) (State) (Zip)																				
		Tab	le I - N	lon-Der	ivativ	e Sec	curit	ties Ac	quire	ed, D	isposed o	of, or B	eneficia	lly O	wned					
Date				2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			Benefici		es For ially (D) Following (I) (rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3		tion(s)			Instr. 4)	
Common Stock 09/0				09/09/2	2021	21			М		5,985	Α	\$10.57 15		15,	200		D		
Common Stock 09/09/20				2021	1			М		13,124	A	\$12.7		28,	8,324		D			
Common Stock 09/09/				2021	!1			S ⁽¹⁾		19,109	D	\$16.744	\$16.7448 ⁽²⁾ 9		215		D			
		-	Table I								posed of, , convertil			y Ow	vned					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Mont		3A. Deemed Execution Date,		4. Transa	ransaction code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$10.57	09/09/2021			М			5,985	(3)		06/10/2030	Commo Stock	ⁿ 5,985	4	\$0.00	0		D		
Stock Option (right to buy)	\$12.7	09/09/2021			М		13,124		(4)		02/13/2030	Commo Stock	ⁿ 13,124		\$0.00	21,876		D		

Explanation of Responses:

 $1.\ A$ portion of the shares was sold to satisfy the exercise price of the stock options.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.53 to \$16.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

3. This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021.

4. The option vested with respect to 25% of the underlying shares on February 14, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

Remarks:

<u>/s/ Stephen Ray Mitchell</u>

** Signature of Reporting Person

09/13/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.